Brukerm?nster for ?strogen i og etter overgangsalderen i Norge

摘要

SAMMENDRAGBakgrunn: Materiale og metode: Resultater: Konklusjon: Prevalence of Hormone Replacement Therapy (HRT) in Norwegian women 45-64years old: User characteristics and choices of therapy. The Norwegian Women and Cancer Study(NOWAC) 1996-97.?Nor J Epidemiol 2001; 11 (1): 81-90. ENGLISH SUMMARYBackground and objectives: Material and methods: Results: Conclusion: Our results suggest that user patterns are rapidly changing in Norway, and HRT has become a choicefor many women. More than four out of ten women reported ever use of systemic or local HRT, and one out ofthree reported current use. Socio-economic differences between users and non-users seem to disappear in womenunder 55 years of age, but persist in the older age groups. Short time use still dominates, but perhaps not for somuch longer.Current use of systemic HRT was reported by 27.3% of the women while 38.0% reported ever use. Thehighest prevalence was in the age group 55-59 years where 35.6% were current users. More than 60% of thewomen were classified as postmenopausal, two thirds of them naturally postmenopausal. Mean duration oftreatment was found to be approximately two years among earlier users but had increased to 4.5 years amongcurrent users. Still the majority of women has not been using HRT beyond five years. Prevalence of use washigher among earlier OC users, smokers, lean women and in households with high income. Among older women,users had higher education than non-users, while this difference disappeared in the youngest women. Fixedcombinations of estradiol and noretisteroneacetate either cyclic or continuous, are used by six out of ten users.A random sample of 18,199 Norwegian women aged 45-64 years responded to a postalquestionnaire in 1996-97. The questionnaire included questions about menstruation status and fertility, oralcontraceptives (OC) and HRT use, lifestyle, health and socioeconomic variables. The response rate was 60%.There has been a considerable increase in the sale of non-contraceptive estrogens inNorway during the last ten years. We wanted to assess the prevalence of HRT in Norwegian women 45-64 yearsand examine factors related to use.Vi finner at brukerprevalens ?kte med 4% fra 1996 til 1997, og bruksm?nster for ?strogen rundtovergangsalderen synes ? endres i nye generasjoner av brukere. Tre av ti kvinner i aktuell alder bruker systemiskbehandling med slike midler i dag. Det kan se ut til at sosio?konomiske faktorers betydning for bruk minsker,mens behandlingslengden ?ker.Bakken K, Eggen AE.?Systemisk behandling gir 27,3% n?v?rende brukere, mens hele 38,0% har brukt slik midler noengang. Gjennomsnittlig brukstid varierer fra ca. 2 ?r hos tidligere brukere til ca. 4,5 ?r hos de som bruker n?.Brukere ser ut til ? v?re slankere og ha h?yere husholdsinntekt enn ikke-brukere, i tillegg til at de oftere har bruktp-piller og r?kt. Blant de eldste kvinnene er brukere ogs? karakterisert ved h?yere utdannelsesniv?.”Kvinner og kreft” er en prospektiv populasjonsstudie basert p? utsendte sp?rreskjema til ettilfeldig utvalg av norske kvinner mellom 30-70 ?r. Unders?kelsen har p?g?tt siden 1992, og mer enn 100 000kvinner har bidratt med svar. Artikkelen er basert p? data fra et utvalg p? 18 199 kvinner i alderen 45-64 ?r sombesvarte sp?rreskjema utsendt i 1996-97. Svarprosenten var 60%.Salgstall for ?strogenholdige preparater knyttet til overgangsalderen er firedoblet i l?pet av de siste 10?r. ?strogens rolle i forebyggende behandling av kroniske sykdommer i alderdommen, for eksempel hjertekarsykdomog osteoporose, fokuseres stadig mer. Artikkelen presenterer prevalenstall for bruk, brukerkarakteristikaog varighet av behandlingen.